Masimo Corporation $MASI Shares Sold by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP cut its stake in Masimo Corporation (NASDAQ:MASI) by 5.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 708,300 shares of the medical equipment provider’s stock after selling 39,198 shares during the quarter. Masimo makes up approximately 1.7% of Liontrust Investment Partners LLP’s portfolio, making the stock its 22nd largest holding. Liontrust Investment Partners LLP owned approximately 1.30% of Masimo worth $119,150,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MASI. Deutsche Bank AG lifted its position in shares of Masimo by 1.5% in the first quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock valued at $1,051,000 after acquiring an additional 92 shares in the last quarter. Nuveen LLC acquired a new position in Masimo in the 1st quarter valued at $25,830,000. Russell Investments Group Ltd. lifted its holdings in Masimo by 76.4% in the 1st quarter. Russell Investments Group Ltd. now owns 34,747 shares of the medical equipment provider’s stock valued at $5,789,000 after purchasing an additional 15,044 shares in the last quarter. Vestmark Advisory Solutions Inc. boosted its stake in Masimo by 6.1% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 3,274 shares of the medical equipment provider’s stock worth $545,000 after purchasing an additional 189 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Masimo by 8.6% during the first quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider’s stock worth $117,172,000 after buying an additional 55,658 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on MASI. Bank of America began coverage on shares of Masimo in a research note on Monday, November 17th. They issued a “neutral” rating and a $162.00 price target on the stock. Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. BTIG Research boosted their target price on Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $190.00 price target on shares of Masimo in a report on Friday, December 5th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Masimo presently has an average rating of “Hold” and an average price target of $189.40.

Masimo Stock Performance

Masimo stock opened at $138.34 on Friday. The firm has a 50 day simple moving average of $145.31 and a 200-day simple moving average of $151.44. The stock has a market cap of $7.43 billion, a price-to-earnings ratio of -13.13, a price-to-earnings-growth ratio of 1.50 and a beta of 1.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92. Masimo Corporation has a 1-year low of $133.70 and a 1-year high of $194.88.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. The firm had revenue of $617.00 million for the quarter. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. On average, analysts expect that Masimo Corporation will post 4.1 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.